Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer.

Eldar-Geva T, Liberty G, Chertin B, Fridmans A, Farkas A, Margalioth EJ, Spitz IM

European journal of endocrinology9 Oct 2009Cited by 13 (Europe PMC)

PMID19820037DOI10.1530/eje-09-0366PepBankPUB-19820037

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In ten men with prostate cancer, FSH, which had increased during antiandrogen treatment, initially fell after histrelin implant insertion.
In plain wordsIn ten men with prostate cancer, FSH first fell after histrelin implant insertion, compared with levels during earlier antiandrogen treatment.
Peptide
Histrelin
Outcome
DecreaseFSH after implant insertion
Study
n = 10
Comparator
Levels during antiandrogen (flutamide) administration before insertion
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
FSH, inhibin B, and testosterone increased during antiandrogen administration and levels fell after implant insertion.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients aged 77+/-7 (means+/-S.E.M.) years with prostate cancer were treated with the GnRHa histrelin for at least a year.
Summary · context
Two weeks prior to insertion and for 3-4 months following removal the patients were treated with the antiandrogen flutamide.
Report a problemFND-1982003701
02HumanNon-randomized trialEfficacy outcome
In ten men with prostate cancer, inhibin B, which had increased during antiandrogen treatment, fell after histrelin implant insertion.
In plain wordsIn ten men with prostate cancer, inhibin B fell after histrelin implant insertion, compared with levels during earlier antiandrogen treatment.
Peptide
Histrelin
Outcome
DecreaseInhibin B after implant insertion
Study
n = 10
Comparator
Levels during antiandrogen (flutamide) administration before insertion
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
FSH, inhibin B, and testosterone increased during antiandrogen administration and levels fell after implant insertion.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients aged 77+/-7 (means+/-S.E.M.) years with prostate cancer were treated with the GnRHa histrelin for at least a year.
Summary · context
Two weeks prior to insertion and for 3-4 months following removal the patients were treated with the antiandrogen flutamide.
Report a problemFND-1982003702
03HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, testosterone fell after histrelin implant insertion.
In plain wordsIn men with prostate cancer, testosterone fell after histrelin implant insertion.
Peptide
Histrelin
Outcome
DecreaseTestosterone after implant insertion
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · at least a yearAs given in this study (human).
Source sentences
Summary
FSH, inhibin B, and testosterone increased during antiandrogen administration and levels fell after implant insertion.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients aged 77+/-7 (means+/-S.E.M.) years with prostate cancer were treated with the GnRHa histrelin for at least a year.
Summary · context
Two weeks prior to insertion and for 3-4 months following removal the patients were treated with the antiandrogen flutamide.
Report a problemFND-1982003703
04HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, FSH gradually increased four weeks after histrelin implant insertion.
In plain wordsIn men with prostate cancer, FSH gradually increased four weeks after histrelin implant insertion.
Peptide
Histrelin
Outcome
IncreaseFSH during continued implant use
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Four weeks post insertion, FSH gradually increased while inhibin B and testosterone remained fully suppressed.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients aged 77+/-7 (means+/-S.E.M.) years with prostate cancer were treated with the GnRHa histrelin for at least a year.
Summary · context
Two weeks prior to insertion and for 3-4 months following removal the patients were treated with the antiandrogen flutamide.
Report a problemFND-1982003704
05HumanNon-randomized trialEfficacy outcome
In men with prostate cancer receiving histrelin, inhibin B remained fully suppressed four weeks after insertion.
In plain wordsIn men with prostate cancer receiving histrelin, inhibin B remained fully suppressed four weeks after implant insertion.
Peptide
Histrelin
Outcome
DecreaseInhibin B during continued implant use
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Four weeks post insertion, FSH gradually increased while inhibin B and testosterone remained fully suppressed.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients aged 77+/-7 (means+/-S.E.M.) years with prostate cancer were treated with the GnRHa histrelin for at least a year.
Summary · context
Two weeks prior to insertion and for 3-4 months following removal the patients were treated with the antiandrogen flutamide.
Report a problemFND-1982003705
06HumanNon-randomized trialEfficacy outcome
In men with prostate cancer receiving histrelin, testosterone remained fully suppressed four weeks after insertion.
In plain wordsIn men with prostate cancer receiving histrelin, testosterone remained fully suppressed four weeks after implant insertion.
Peptide
Histrelin
Outcome
DecreaseTestosterone during continued implant use
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Four weeks post insertion, FSH gradually increased while inhibin B and testosterone remained fully suppressed.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients aged 77+/-7 (means+/-S.E.M.) years with prostate cancer were treated with the GnRHa histrelin for at least a year.
Summary · context
Two weeks prior to insertion and for 3-4 months following removal the patients were treated with the antiandrogen flutamide.
Report a problemFND-1982003706
07HumanNon-randomized trialEfficacy outcome
In men with prostate cancer, AMH increased after histrelin implant insertion and remained elevated throughout implant use.
In plain wordsIn men with prostate cancer, AMH increased after histrelin implant insertion and remained elevated during use.
Peptide
Histrelin
Outcome
IncreaseAMH during implant use
Study
n = 10
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · at least a yearAs given in this study (human).
Source sentences
Summary
AMH levels did not change during antiandrogen treatment, but increased following implant insertion and remained elevated for the duration of implant use.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten patients aged 77+/-7 (means+/-S.E.M.) years with prostate cancer were treated with the GnRHa histrelin for at least a year.
Summary · context
Two weeks prior to insertion and for 3-4 months following removal the patients were treated with the antiandrogen flutamide.
Report a problemFND-1982003707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.